| Bioactivity | c-ABL-IN-3 is a potent inhibitor of c-Abl. Activation of c-Abl has been implicated in various diseases, notably cancer. c-ABL-IN-3 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2021048567A1, compound 50)[1]. |
| Name | c-ABL-IN-3 |
| CAS | 2626934-64-1 |
| Formula | C17H11F3N4O3 |
| Molar Mass | 376.29 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Michael J. RAWLING, et al. New compounds and methods. Patent WO2021048567A1. |
c-ABL-IN-3
CAS: 2626934-64-1 F: C17H11F3N4O3 W: 376.29
c-ABL-IN-3 is a potent inhibitor of c-Abl. Activation of c-Abl has been implicated in various diseases, notably cancer.
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.